Haemonetics Corporation (HAE) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, and thank you for standing by. Welcome to the Q4 2025 Humanitics Corporation Earnings Conference Call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there'll be a question and answer session. To ask a question during the session, you'll need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To answer your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to turn the conference over to Ola Gayed, Vice President of Investor Relations and Treasury. Please go ahead. Good morning, and thank you all for joining us for Humanetics' fourth quarter and fiscal year 2025 conference call and webcast. I'm joined today by Chris Simon, our CEO, and James Durecka, our CFO. This morning, we posted our fourth quarter and fiscal year 2025 results to our investor relations website, along with additional supplemental tables that support some of the assumptions within our fiscal year 2026 guidance included in our earnings release. These supplemental tables help reconcile the projected fiscal year 2026 growth rates of electrophysiology, coronary, and peripheral procedures in the U.S. with the corresponding exercise opportunities for our vascular closure business. The exercise opportunities represent the anticipated growth of the U.S. addressable market industrial closure as incorporated in our hospital and total company revenue guidance for fiscal year 2026. Before we begin, just a quick reminder that all revenue growth rates discussed today are organic, unless specified otherwise, and exclude the impact of currency fluctuation, acquisitions, and impacts of the whole blood divestiture. We'll also refer to other non-...